IBDEI15R ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19695,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,19695,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,19695,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,19696,0)
 ;;=E06.0^^84^921^53
 ;;^UTILITY(U,$J,358.3,19696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19696,1,3,0)
 ;;=3^Thyroiditis,Acute
 ;;^UTILITY(U,$J,358.3,19696,1,4,0)
 ;;=4^E06.0
 ;;^UTILITY(U,$J,358.3,19696,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,19697,0)
 ;;=E06.1^^84^921^54
 ;;^UTILITY(U,$J,358.3,19697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19697,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,19697,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,19697,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,19698,0)
 ;;=C73.^^84^921^37
 ;;^UTILITY(U,$J,358.3,19698,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19698,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,19698,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,19698,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,19699,0)
 ;;=E10.21^^84^921^8
 ;;^UTILITY(U,$J,358.3,19699,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19699,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,19699,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,19699,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,19700,0)
 ;;=E10.9^^84^921^12
 ;;^UTILITY(U,$J,358.3,19700,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19700,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,19700,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,19700,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,19701,0)
 ;;=E11.21^^84^921^17
 ;;^UTILITY(U,$J,358.3,19701,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19701,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,19701,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,19701,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,19702,0)
 ;;=E11.39^^84^921^18
 ;;^UTILITY(U,$J,358.3,19702,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19702,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,19702,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,19702,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,19703,0)
 ;;=E11.43^^84^921^15
 ;;^UTILITY(U,$J,358.3,19703,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19703,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,19703,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,19703,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,19704,0)
 ;;=E11.59^^84^921^13
 ;;^UTILITY(U,$J,358.3,19704,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19704,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,19704,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,19704,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,19705,0)
 ;;=E11.618^^84^921^14
 ;;^UTILITY(U,$J,358.3,19705,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19705,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,19705,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,19705,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,19706,0)
 ;;=E11.621^^84^921^16
 ;;^UTILITY(U,$J,358.3,19706,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19706,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,19706,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,19706,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,19707,0)
 ;;=E11.622^^84^921^20
 ;;^UTILITY(U,$J,358.3,19707,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19707,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,19707,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,19707,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,19708,0)
 ;;=E11.65^^84^921^19
 ;;^UTILITY(U,$J,358.3,19708,1,0)
 ;;=^358.31IA^4^2
